Literature DB >> 26313385

Poor responders in IVF--is there any evidence-based treatment for them?

Iwona Szymusik1, Piotr Marianowski1, Aleksandra Zygula1, Miroslaw Wielgos1.   

Abstract

Despite the vast experience in controlled ovarian hyperstimulation, there are still women who respond poorly to gonadotropins, which results in few oocytes at retrieval, reduced number of embryos for transfer and consequently unsatisfactory pregnancy rates. Although such patients are quite common in IVF practice, the exact prevalence of so-called "poor responders" is difficult to estimate due to the variety of applied definitions. The urgent need for an internationally accepted definition of poor ovarian response (POR) was addressed by an ESHRE Workshop held in Bologna in 2010, where the consensus was reached and criteria were finally established. The application of this uniform definition may allow a correct estimate of POR prevalence and, what is more important, designing proper trials to assess and finally compare the interventions used in POR patients. The article describes the possible physiology of POR and patient characteristics, mentions risk factors and laboratory tests of decreased ovarian reserve. Finally it reviews the possible management of POR with different stimulation protocols in the light of EBM. Basing on published meta-analyses, various additional alternatives (such as estradiol priming, the addition of rLH, growth hormone, androgens and androgen-modulating agents, aspirin) are also summarized. Despite the two decades of trying, there is still no consensus on what is best for POR. No single treatment can be recommended over another, as the evidence for all of them is insufficient. It is obvious that interventions used in POR require properly designed large randomized studies, because until now there is no evidence-based treatment for that particular group of patients.

Entities:  

Mesh:

Year:  2015        PMID: 26313385

Source DB:  PubMed          Journal:  Neuro Endocrinol Lett        ISSN: 0172-780X            Impact factor:   0.765


  6 in total

1.  Effect of follicular flushing on reproductive outcomes in patients with poor ovarian response undergoing assisted reproductive technology.

Authors:  Anna L M Souza; Marcos Sampaio; Graciele B Noronha; Ludiana G R Coster; Roberta S G de Oliveira; Selmo Geber
Journal:  J Assist Reprod Genet       Date:  2017-07-21       Impact factor: 3.412

2.  Response: Commentary: Efficacy of Follicle-Stimulating Hormone (FSH) Alone, FSH + Luteinizing Hormone, Human Menopausal Gonadotropin or FSH + Human Chorionic Gonadotropin on Assisted Reproductive Technology Outcomes in the "Personalized" Medicine Era: A Meta-analysis.

Authors:  Daniele Santi; Livio Casarini; Carlo Alviggi; Manuela Simoni
Journal:  Front Endocrinol (Lausanne)       Date:  2018-03-23       Impact factor: 5.555

3.  Efficacies of different ovarian hyperstimulation protocols in poor ovarian responders classified by the POSEIDON criteria.

Authors:  Fei Li; Tian Ye; Huijuan Kong; Jing Li; Linli Hu; HaiXia Jin; Yingchun Su; Gang Li
Journal:  Aging (Albany NY)       Date:  2020-05-29       Impact factor: 5.682

4.  Nicotinamide Supplementation Improves Oocyte Quality and Offspring Development by Modulating Mitochondrial Function in an Aged Caenorhabditis elegans Model.

Authors:  Hyemin Min; Mijin Lee; Kyoung Sang Cho; Hyunjung Jade Lim; Yhong-Hee Shim
Journal:  Antioxidants (Basel)       Date:  2021-03-26

5.  Effect of Antagonist Start Day on Cycle Outcomes in Poor Responders.

Authors:  Inci Kahyaoglu; Hatice Y Dogru; Iskender Kaplanoglu; Ayse Seval Ozgu-Erdinc; Serdar Dilbaz; Leyla Mollamahmutoglu
Journal:  J Hum Reprod Sci       Date:  2021-12-31

6.  Pretreatment with coenzyme Q10 improves ovarian response and embryo quality in low-prognosis young women with decreased ovarian reserve: a randomized controlled trial.

Authors:  Yangying Xu; Victoria Nisenblat; Cuiling Lu; Rong Li; Jie Qiao; Xiumei Zhen; Shuyu Wang
Journal:  Reprod Biol Endocrinol       Date:  2018-03-27       Impact factor: 5.211

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.